Best Practice & Research Clinical Haematology
Volume 20, Issue 4 , Pages 665-680 , December 2007

Multiple myeloma: New staging systems for diagnosis, prognosis and response evaluation

  • S. Vincent Rajkumar, MD (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 507 284 2511; Fax: +1 507 266 4972.
    • ,
  • Francis Buadi, MD (Senior Associate Consultant)

References 

  1. Kyle RA, Rajkumar SV. Multiple myeloma. The New England Journal of Medicine. 2004;351:1860–1873
  2. Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia. 2006;20:1341–1352
  3. Bruno B, Giaccone L, Rotta M, et al. Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. Leukemia. 2005;19:1729–1738
  4. Kyle RA. Five decades of therapy for multiple myeloma: a paradigm for therapeutic models. Leukemia. 2005;19:910–912
  5. Rajkumar SV. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. Hematology. American Society of Hematology. Education Program. 2005;340–345
  6. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings. 2003;78:21–33
  7. Kyle RA. Long-term survival in multiple myeloma. The New England Journal of Medicine. 1983;308:314–316
  8. Attal M, Payen C, Facon T, et al. Single versus double transplant in myeloma: A randomized trial of the ‘Inter Groupe Francais du Myelome’ (IFM). Blood. 1997;90(Suppl 1):418a
  9. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55–65
  10. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008–4010
  11. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–854
  12. Kyle RA. Prognostic factors in multiple myeloma. Stem Cells. 1995;2:56–63
  13. Rapoport BL, Falkson HC, Falkson G. Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patients. South African Medical Journal. 1990;79:65–67
  14. Greipp PR, San Miguel JF, Durie BG, et al. International staging system for multiple myeloma. Journal of Clinical Oncology. 2005;23:3412–3420
  15. Rajkumar SV, Kyle RA. Multiple myeloma: diagnosis and treatment. Mayo Clinic Proceedings. 2005;80:1371–1382
  16. Greipp PR. Prognosis in myeloma. [Review] [75 refs] Mayo Clinic Proceedings. 1994;69:895–902
  17. Greipp PR, Gaillard JP, Klein B, et al. Independent prognostic value for plasma cell labeling index (PCLI), immunofluorescence microscopy plasma cell percent (IMPCP), beta 2-microglobulin (B2M), soluble interleukin-6 receptor (sIL-6R), and c-reactive protein (CRP) in myeloma trial E9487 (Meeting abstract). Blood. 1994;84
  18. Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology–an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91:2501–2507
  19. Greipp PR, Lust JA, O'Fallon WM, et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. [see comments] Blood. 1993;81:3382–3387
  20. Greipp PR, Witzig TE, Gonchoroff NJ. Immunofluorescent plasma cell labeling indices (Li) using a monoclonal antibody (Bu-1). American Journal of Hematology. 1985;20:289–292
  21. Greipp PR, Gaillard JP, Kalish LA, et al. Independent prognostic value for serum soluble interleukin-6 receptor (sIL-6R) in Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9487 (Meeting abstract). Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1993;12
  22. Greipp PR, Katzmann JA, O′Fallon WM, et al. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood. 1988;72:219–223
  23. Greipp PR, Witzig TE, Gertz MA, et al. Clinical application of cell kinetics to patients with monoclonal gammopathy and multiple myeloma. Cell and Tissue Kinetics. 1990;23:348
  24. Boccadoro M, Marmont F, Tribalto M, et al. Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis. Journal of Clinical Oncology. 1989;7:119–125
  25. Boccadoro M, Marmont F, Tribalto M, et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. Journal of Clinical Oncology. 1991;9:444–448
  26. Latreille J, Barlogie B, Johnston D, et al. Ploidy and proliferative characteristics in monoclonal gammopathies. Blood. 1982;59:43–51
  27. Cornelissen JJ, Sonneveld P, Schoester M, et al. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. Journal of Clinical Oncology. 1994;12:115–119
  28. Montecucco C, Riccardi A, Ucci G, et al. Analysis of human myeloma cell population kinetics. Acta Haematologica (Basel). 1986;75:153–156
  29. Tricot G, Sawyer JR, Jagannath S, et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. Journal of Clinical Oncology. 1997;15:2659–2666
  30. Rajkumar SV, Fonseca R, Lacy MQ, et al. Abnormal cytogenetics predict for poor survival after peripheral stem cell transplantation in relapsed multiple myeloma. Blood. 1997;90(Suppl 1):527a
  31. Simpson DR, Berkahn LC, Squire J, et al. Prognostic significance of cytogenetics in patients with multiple myeloma referred for autologous stem cell transplant (ABMT). Blood. 1997;90(Suppl 1):527a
  32. Gutierrez NC, Castellanos MV, Martin ML, et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia. 2006;21:143–150
  33. Ross FM, Ibrahim AH, Vilain-Holmes A, et al. Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma. Leukemia. 2005;19:1634–1642
  34. Seong C, Delasalle K, Hayes K, et al. Prognostic value of cytogenetics in multiple myeloma. British Journal of Haematology. 1998;101:189–194
  35. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 1995;86:4250–4256
  36. Shaughnessy J, Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. British Journal of Haematology. 2003;120:44–52
  37. Chng WJ, Santana-Davila R, Van Wier SA, et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia. 2006;20:807–813
  38. Chiecchio L, Protheroe RKM, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006;20:1610–1617
  39. Fonseca R, Oken MM, Harrington D, et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia. 2001;15:981–986
  40. Avet-Louseau H, Daviet A, Sauner S, et al. Intergroupe Francophone du M Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. British Journal of Haematology. 2000;111:1116–1117
  41. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Research. 2004;64:1546–1558
  42. Zhan F, Sawyer J, Tricot G. The role of cytogenetics in myeloma. Leukemia. 2006;20:1484–1486
  43. Dispenzieri A. An internationally recognized uniform cytogenetic classification system is needed for multiple myeloma. Leukemia. 2007;21:9–11
  44. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97:1566–1571
  45. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107:3474–3480
  46. Kroger N, Schilling G, Einsele H, et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood. 2004;103:4056–4061
  47. Bensinger WI. The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia. 2006;20:1683–1689
  48. Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia. 2006;21:164–168
  49. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2006;21:151–157
  50. Smadja NV, Bastard C, Brigaudeau C, et al. Groupe Francais de Cytogenetique H Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98:2229–2238
  51. Debes-Marun CS, Dewald GW, Bryant S, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia. 2003;17:427–436
  52. Fassas AB, Spencer T, Sawyer J, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. British Journal of Haematology. 2002;118:1041–1047
  53. Trendle MC, Leong T, Kyle RA, et al. Hypodiploid myeloma revisited: response to therapy and survival in Eastern Cooperative Oncology Group Study E9486. Blood. 1996;88(Suppl 1):390a;(A1549)
  54. Drach J, Schuster J, Nowotny H, et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Research. 1995;55:3854–3859
  55. Drach J, Angerler J, Schuster J, et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood. 1995;86:3915–3921
  56. Zandecki M. Multiple myeloma-almost all patients are cytogenetically abnormal. British Journal of Haematology. 1996;94:217–227
  57. Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20:2034–2040
  58. Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14) (p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003;101:1520–1529
  59. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569–4575
  60. Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100:1579–1583
  61. Drach J, Ackermann J, Fritz E, et al. Presence of a P53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802–809
  62. Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): Consensus Statement. Mayo Clinic Proceedings. 2007;82:323–341
  63. Anonymous . Proposed guidelines for protocol studies. I. Introduction. II. Plasma cell myeloma. 3. Chronic lymphocytic leukemia. IV. Chronic granulocytic leukemia. Cancer Chemotherapy Reports. Part 3. 1973;4:141–173
  64. Alexanian R, Bonnet J, Gehan E, et al. Combination chemotherapy for multiple myeloma. Cancer. 1972;30:382–389
  65. McLaughlin P, Alexanian R. Myeloma protein kinetics following chemotherapy. Blood. 1982;60:851–855
  66. Oken MM, Kyle RA, Greipp PR, et al. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma. Leukemia & Lymphoma. 1996;20:447–452
  67. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology. 1998;102:1115–1123
  68. Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473
  69. Durie BGM, Rajkumar SV. Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide by H Prince, Brad Schenkel and Linda Mileshkin. Leukemia. 2007;21:821
  70. Abraham RS, Clark RJ, Bryant SC, et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clinical Chemistry. 2002;48:655–657
  71. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clinical Chemistry. 2002;48:1437–1444
  72. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. The New England Journal of Medicine. 2003;348:1875–1883
  73. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. The New England Journal of Medicine. 1996;335:91–97
  74. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. [see comment] The New England Journal of Medicine. 2003;349:2495–2502
  75. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine. 2003;348:2609–2617
  76. Kumar S, Gertz MA, Dispenzieri A, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. [comment] Mayo Clinic Proceedings. 2003;78:34–39
  77. The International Myeloma Working Group . Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology. 2003;121:749–757
  78. Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15:1274–1276
  79. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology. 2003;30:110–115
  80. Baldini L, Goldaniga M, Guffanti A, et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. Journal of Clinical Oncology. 2005;23:4662–4668
  81. Gobbi PG, Baldini L, Broglia C, et al. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?. Clinical Cancer Research. 2005;11:1786–1790
  82. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis of monoclonal gammopathy of undetermined significance. The New England Journal of Medicine. 2002;346:564–569
  83. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003;102:3759–3764
  84. Dimopoulos MA, Moulopoulos LA, Maniatis A, et al. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96:2037–2044
  85. Kyle RA, Rajkumar SV. Plasma cell disorders. In:  Goldman L,  Ausiello D editor. Cecil textbook of medicine. 22nd edn.. Philadelphia: W.B. Saunders; 2004;p. 1184–1195
  86. Dispenzieri A. POEMS syndrome. Hematology. American Society of Hematology. Education Program. 2005;360–367

PII: S1521-6926(07)00077-1

doi: 10.1016/j.beha.2007.10.002

Best Practice & Research Clinical Haematology
Volume 20, Issue 4 , Pages 665-680 , December 2007

Article Tools